← Leaderboards
Adam Shilling
Nanocan Therapeutics Corporation
$732,767
Attributed
$1,798,461
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $998.8K · FY2022–25$1M$750K$500K$250K$0
'22
'23
'24
'25
Funding mix
By agency
NIH$1,798,461 · 3
By mechanism
R42$1,398,461 · 2
R41$400,000 · 1
Top collaborators
- Wilfred Ngwa3 shared
- Akila Viswanathan1 shared
Others in their field
Other Rising Stars on “Neoantigens”
- Amar Nijagal · University Of California, San Francisco$3,176,680
- Jennifer K Hoffman · Duke University$2,964,074
- Eileen Mary O'Reilly · Sloan-Kettering Inst Can Research$2,300,843
- Hua Wang · University Of Illinois At Urbana-Champaign$2,229,562
- David Braun · Yale University$1,946,815
- Xiaoxiao Wan · Washington University$1,810,485
Research focus
NeoantigensToxic EffectInnovationNanoparticleSafetyTechnologyDoseImmunotherapyIn Situ VaccinationMalignant NeoplasmsNeoplasm MetastasisRadiation TherapyBiocompatible MaterialsDisparity ReductionAnimalsClinical TrialsAnti-Cd40Health Services AccessibilityCancer CareCostCollaborationsCancer PatientDistantTumor
Grant awards (3)
Liquid Immunotherapeutic Fiducial Eluter (LIFE) Gel for Cervical Cancer$998,781
R42 · FY2025 · CA · contact PI
Liquid Immunogenic Fiducial Eluter (LIFE) for Cervical Cancer Treatment$400,000
R41 · FY2022 · CA · contact PI
Radio-immunotherapy dose-painting (RAID) treatment for hormonal resistant prostate cancer$399,680
R42 · FY2022 · CA · contact PI